Amber Specialty Pharmacy, Hy-Vee Pharmacy Solutions to administer Regeneron monoclonal antibody treatment

Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions today announced the launch of a COVID-19 response specifically to assist hospitals and physicians throughout the United States with dispensing and coordinating the administration of Regeneron’s monoclonal antibody treatment, REGEN-COV (casirivimab and imdevimab), to eligible patients.

[Read more: Hy-Vee names 1st chief medical officer]

According to the Food and Drug Administration, Regeneron's treatment has proven to reduce viral levels and improve symptoms in non-hospitalized COVID patients. As COVID-19 infections continue, hospitals and physicians are turning to pharmacies to help treat infected and exposed patients who are eligible to receive the Regeneron treatment.

REGEN-COV should be received as soon as possible or within 10 days of a positive COVID-19 diagnosis for best results. It is also authorized for post-exposure prophylaxis of COVID-19 individuals who are not fully vaccinated or who are not expected to mount an adequate immune response to complete vaccination.

REGEN-COV is available in a clinic setting or as an in-home treatment, and requires a one-hour observation period. The treatment is covered by insurance plans and Medicare.

[Read more: Amber Specialty Pharmacy to dispense Kadmon's Rezurock]

Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions have 21 locations in the United States and Puerto Rico. All locations are licensed to administer the Regeneron antibody treatment.

“Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions are proud to be part of the COVID-19 response, positively impacting the lives of the communities we serve,” said Kristin Williams, president of Amber Specialty Pharmacy and chief health officer at Hy-Vee.